TQ Course | Therapeutic Innovations: The Game Changers (Nashville 2022) by Innereactive | Oct 24, 2022 | 2022 Nashville, TQ Courses | 0 comments "*" indicates required fields HiddenAdvanced Dry Eye Treatment and ManagementHiddenDate (Hidden) MM slash DD slash YYYY HiddenEvent Date (Hidden) MM slash DD slash YYYY HiddenEvent 60 days past date (Hidden) MM slash DD slash YYYY HiddenEvent Date Difference (Hidden)1. Humira (adalimumab) subcutaneous injection is on label for which ocular diagnosis?* A - Noninfectious posterior uveitis B - Diabetic macular edema C - RPE65 biallelic mutation D - Exudative macular degeneration 2. What is the difference between generic latanoprost 0.005% and Xelpros (latanoprost ophthalmic emulsion 0.005%)?* A - Mechanism of action B - Preservative C - Active ingredient D - Dosage 3. The most common side effect of Rho kinase inhibitors is:* A - Corneal verticillata B - Conjunctival hyperemia C - Intraocular inflammation D - Iris color change 4. What is the trade name of the intracameral bimatoprost sustained-release implant?* A - Durysta B - Durezol C - Dexycu D - DARPin 5. Following three monthly loading dose injections of Beovu (brolucizumab), the on-label dosing for neovascular macular degeneration is:* A - Every two weeks B - Every four weeks C - Every twelve weeks D - Every sixteen weeks 6. Which of the following is NOT part of the general trend in the development of new therapies in retinal vascular disease?* A - Decreased amount of time between treatments B - Development of alternative routes of administration of medication C - Improvement of patient quality of life D - Reduction in the cost of treatment 7. Advantages of smaller molecule anti-VEGF agents include:* A - Higher systemic exposure B - Slower clearance C - Improved tissue penetration D - Greater required medication volume 8. Oxervate (cenegermin-bkbj ophthalmic solution 0.002%) is on label for the treatment of:* A - Thyroid eye disease B - Neurotrophic keratitis C - Dry eye disease D - Herpes simplex epithelial keratitis 9. Rocklatan (netarsudil 0.02%/latanoprost 0.005%) dosage is correctly described as:* A - Every other day B - Once daily in the evening C - Twice daily D - Three times daily 10. Emerging treatment options for presbyopia include which of the following classes of medications?* A - Beta blockers B - Cholinergics C - Steroids D - Fluoroquinolones 11. What is the name of the recently FDA-approved agent for the treatment of neovascular macular degeneration?* A - Faricimab B - Tocilizumab C - Teprotumumab D - Bevacizumab 12. Adverse effects of intravitreal anti-VEGF injection include all but which of the following?* A - Elevated intraocular pressure B - Endophthalmitis C - Subconjunctival hemorrhage D - Myopia 13. What is the standard drop size of an ophthalmic solution?* A - 0.01mL B - 0.05mL C - 0.1mL D - 0.5mL 14. Dextenza (dexamethasone ophthalmic insert) 0.4mg is FDA-approved for which of the following indications?* A - Treatment of ocular pain and inflammation following ocular surgery only B - Treatment of diabetic macular edema only C - Treatment of ocular pain and inflammation following ocular surgery and treatment of ocular itching associated with allergic conjunctivitis D - Treatment of diabetic macular edema and treatment of ocular itching associated with allergic conjunctivitis 15. Tepezza (teprotumumab-trbw) is administered by which route?* A - Topical ophthalmic route B - Oral route C - Intravenous infusion D - Subcutaneous injection 16. Side effects of systemically administered steroids include all of the following, EXCEPT:* A - Weight loss B - Hyperglycemia C - Lower resistance to infection D - Changes in mood 17. Long-term use of topical ocular medications preserved with benzalkonium chloride (BAK) may cause which of the following?* A - Decreased goblet cell density B - Increased intraocular pressure C - Cystoid macular edema D - Hyperopic shift 18. Which class of intraocular pressure lowering medication is associated with the best adherence at FDA approved dosing?* A - Prostaglandin analogs B - Carbonic anhydrase inhibitors C - Alpha adrenergic agonists D - Fixed combination medications 19. Activation of the complement system ultimately leads to which cellular process?* A - Apoptosis B - Mitosis C - Respiration D - Transcription 20. FDA-approved biosimilars are available for which of the following anti-VEGF agents?* A - Ranibizumab B - Aflibercept C - Brolucizumab D - Faricimab Personal InformationName* First Last Email* Phone*OE Tracker # License # Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationHiddenRetake Code Therapeutic Innovations The Game Changers | TQ Credit*After 12/23/2022 , pricing will increase to $30. Price: (Past 60 Days) Therapeutic Innovations The Game Changers | TQ CreditThis course was presented over 60 days ago. Due to this late submission of TQ, your TQ credit price is $30. Price: Retake Discount Price: (Past 60 Days) Retake Discount Price: Payment MethodPayPal Checkout American ExpressDiscoverMasterCardVisaSupported Credit Cards: American Express, Discover, MasterCard, Visa Card Number Expiration Date Security Code Cardholder Name HiddenCourse Information (HIDDEN)HiddenCourse Name (HIDDEN) HiddenRetake Code (HIDDEN) HiddenQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/) HiddenCE Hours (HIDDEN) Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
